Northwest Biotherapeutics NWBO
OTC NWBO
$0.15 -0.02 (-11.76%)
At close: Oct 22, 2026 · 4:00 PM EDT

Northwest Biotherapeutics (NWBO) Non-Current Deffered Revenue (2018)

Updated

Northwest Biotherapeutics (NWBO) reported Non-Current Deffered Revenue of $4.8 million for Q4 2018.

Analysis

Northwest Biotherapeutics (NWBO) Non-Current Deffered Revenue (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn -
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn -
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn -
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn -
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn -
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn -
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn -
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn -
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn -
10 Northwest Biotherapeutics 250.40 Mn 240.41 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 4.80 Mn
API Access

Northwest Biotherapeutics Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=NWBO&period=max&api_key=YOUR_API_KEY